miv-711
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02705625)
Timeline
Indications
Mechanism of action
- Cathepsin KINHIBITOR
CTSK inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068585 ↗
Also known as
- miv-711
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03443453 | Phase 1 | Jan 19, 2018 | Celerion, Medivir |
| NCT03037489 | Phase 2 | Sep 1, 2016 | Medivir, University of Leeds |
| NCT02705625 | Phase 2 | Jan 1, 2016 | Medivir, University of Leeds |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medivir | For profit | 3 | 3 | 2 | 2016 |
| University of Leeds | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Celerion | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1